Wedge Capital Management L L P NC bought a new position in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 4,959 shares of the biotechnology company’s stock, valued at approximately $298,000.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Janus Henderson Group PLC boosted its stake in Enanta Pharmaceuticals by 8.1% in the 2nd quarter. Janus Henderson Group PLC now owns 944,787 shares of the biotechnology company’s stock worth $79,721,000 after purchasing an additional 70,390 shares during the period. Connor Clark & Lunn Investment Management Ltd. bought a new position in Enanta Pharmaceuticals in the 2nd quarter worth about $224,000. Dupont Capital Management Corp boosted its stake in Enanta Pharmaceuticals by 9.5% in the 2nd quarter. Dupont Capital Management Corp now owns 13,477 shares of the biotechnology company’s stock worth $1,137,000 after purchasing an additional 1,174 shares during the period. JPMorgan Chase & Co. boosted its stake in Enanta Pharmaceuticals by 90.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 109,185 shares of the biotechnology company’s stock worth $9,154,000 after purchasing an additional 52,004 shares during the period. Finally, Pacer Advisors Inc. boosted its stake in Enanta Pharmaceuticals by 31.4% in the 3rd quarter. Pacer Advisors Inc. now owns 5,170 shares of the biotechnology company’s stock worth $311,000 after purchasing an additional 1,234 shares during the period. Institutional investors and hedge funds own 88.62% of the company’s stock.
ENTA has been the subject of several analyst reports. BidaskClub upgraded Enanta Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, September 21st. Zacks Investment Research cut Enanta Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Monday, August 12th. JPMorgan Chase & Co. cut Enanta Pharmaceuticals from a “neutral” rating to an “underweight” rating and lowered their price target for the company from $86.00 to $57.00 in a report on Thursday, September 26th. Berenberg Bank set a $130.00 price target on Enanta Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, September 18th. Finally, ValuEngine raised Enanta Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the stock. Enanta Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $97.20.
Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported $0.33 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.27. The firm had revenue of $44.40 million for the quarter, compared to analyst estimates of $46.98 million. Enanta Pharmaceuticals had a return on equity of 15.16% and a net margin of 29.22%. The business’s quarterly revenue was down 22.5% compared to the same quarter last year. During the same period last year, the company earned $0.97 EPS. Sell-side analysts anticipate that Enanta Pharmaceuticals Inc will post 2.37 earnings per share for the current year.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.
Featured Story: What are no-load funds?
Want to see what other hedge funds are holding ENTA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enanta Pharmaceuticals Inc (NASDAQ:ENTA).
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.